Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RODNEY S DANIEL

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1912094822
CMS profile
40909
Location
OLDSMAR, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$144,949.74

377 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 8; records 101–150 of 377 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RODNEY S DANIEL

NPI 1912094822 · CMS profile ID 40909

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

OLDSMAR, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 377 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912094822?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 377 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912094822?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 377 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912094822?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RODNEY S DANIEL, NPI 1912094822, CMS profile ID 40909, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 377 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1912094822?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

377 matching records · $144,949.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 377 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 377.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $27.4009/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190802117 CMS
E.R. Squibb & Sons, L.L.C. $89.5509/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184960989 CMS
GlaxoSmithKline, LLC. $74.7509/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190347588 CMS
UCB, Inc. $44.0509/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224764302 CMS
GENZYME CORPORATION $104.4109/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380481 CMS
GENZYME CORPORATION $135.3309/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380499 CMS
Mallinckrodt Hospital Products Inc. $21.4509/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211960046 CMS
Novartis Pharmaceuticals Corporation $67.1909/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200125605 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.0609/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222867442 CMS
GENZYME CORPORATION $125.6009/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380501 CMS
PFIZER INC. $10.0309/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229211954 CMS
Amgen Inc. $24.9909/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228360897 CMS
PFIZER INC. $23.5209/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229081086 CMS
UCB, Inc. $0.9409/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224764298 CMS
UCB, Inc. $16.8209/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224764300 CMS
Radius Health, Inc. $27.8209/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249521793 CMS
ANI Pharmaceuticals, Inc. $14.1609/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248631384 CMS
ANI Pharmaceuticals, Inc. $4.1009/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248653891 CMS
AstraZeneca Pharmaceuticals LP $32.2008/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207014102 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $3,135.0008/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1222867524 CMS
PFIZER INC. $2.9208/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229277089 CMS
Amgen Inc. $15.9408/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228360847 CMS
Amgen Inc. $16.7708/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228360879 CMS
Janssen Biotech, Inc. $22.1608/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175177964 CMS
ANI Pharmaceuticals, Inc. $3.2508/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248630033 CMS
Novartis Pharmaceuticals Corporation $26.1408/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200125603 CMS
Novartis Pharmaceuticals Corporation $26.1408/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200125607 CMS
GENZYME CORPORATION $102.0808/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380541 CMS
GENZYME CORPORATION $6,678.0008/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233380543 CMS
GENZYME CORPORATION $572.9608/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380545 CMS
GENZYME CORPORATION $400.8008/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380547 CMS
GENZYME CORPORATION $45.8508/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380549 CMS
GENZYME CORPORATION $28.0008/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380551 CMS
GENZYME CORPORATION $21.0008/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380553 CMS
UCB, Inc. $0.3308/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224764294 CMS
UCB, Inc. $7.1308/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224764296 CMS
Lilly USA, LLC $27.5508/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186906566 CMS
GENZYME CORPORATION $2,862.0008/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233380495 CMS
ABBVIE INC. $243.6008/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201724248 CMS
GENZYME CORPORATION $7,632.0008/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233380487 CMS
GENZYME CORPORATION $316.3308/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380489 CMS
GENZYME CORPORATION $914.2008/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380491 CMS
GENZYME CORPORATION $1,074.2208/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380493 CMS
GENZYME CORPORATION $49.3208/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233380513 CMS
GENZYME CORPORATION $56.0008/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380515 CMS
GENZYME CORPORATION $134.0008/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233380517 CMS
Amgen Inc. $11.4408/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227238096 CMS
Amgen Inc. $25.3808/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228360883 CMS
ANI Pharmaceuticals, Inc. $12.2608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248600690 CMS
ANI Pharmaceuticals, Inc. $1.7608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248650179 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,884.13 344
PY2020 $28,991.20 290
PY2021 $24,014.60 308
PY2022 $70,718.82 328
PY2023 $101,428.20 375
PY2024 $78,899.65 350
PY2025 $144,949.74 377

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $584,620.11 33
PY2024 Recipient $114.46 1
PY2024 Principal investigator $159,238.66 12
PY2023 Principal investigator $51,533.02 2
PY2022 Principal investigator $463.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $13,460.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527756
Principal investigator 1 ABBVIE INC. $1,180.02 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522943
Principal investigator 1 ABBVIE INC. $4,252.50 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522945
Principal investigator 1 GlaxoSmithKline, LLC. $3,024.45 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146671
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,561.50 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190308240
Principal investigator 1 ABBVIE INC. $1,200.00 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202518443
Principal investigator 1 ABBVIE INC. $1,216.00 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202518445
Principal investigator 1 ABBVIE INC. $100.00 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202513769
Principal investigator 1 ABBVIE INC. $13,023.32 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202516349
Principal investigator 1 ABBVIE INC. $7,500.00 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202513139
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,104.90 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190308242
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146667
Principal investigator 1 ABBVIE INC. $3,676.66 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202508518
Principal investigator 1 GlaxoSmithKline, LLC. $3,087.81 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146675
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145544
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192146679
Principal investigator 1 ABBVIE INC. $7,500.00 08/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202503837
Principal investigator 1 GlaxoSmithKline, LLC. $4,257.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145556
Principal investigator 1 ABBVIE INC. $2,280.00 07/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202498700
Principal investigator 1 GlaxoSmithKline, LLC. $3,158.10 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145539
Principal investigator 1 GlaxoSmithKline, LLC. $3,087.81 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145560
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202487869
Principal investigator 1 ABBVIE INC. $13,500.00 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202487871
Principal investigator 1 GlaxoSmithKline, LLC. $3,131.37 05/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145564
Principal investigator 1 Eli Lilly and Company $4,148.83 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877551
Principal investigator 1 Eli Lilly and Company $49,426.00 04/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876791
Principal investigator 1 GlaxoSmithKline, LLC. $818.73 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145548
Principal investigator 1 GlaxoSmithKline, LLC. $11,307.78 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145535
Principal investigator 1 Eli Lilly and Company $5,385.29 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883098
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $200,475.00 01/16/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235998022
Principal investigator 1 GlaxoSmithKline, LLC. $6,219.18 01/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192145552
Principal investigator 1 Eli Lilly and Company $171,228.00 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883096
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,309.86 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190309094